Compare CVNA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | IQV |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Other Specialty Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 35.1B |
| IPO Year | 2017 | 2013 |
| Metric | CVNA | IQV |
|---|---|---|
| Price | $69.14 | $230.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 16 |
| Target Price | ★ $439.67 | $227.13 |
| AVG Volume (30 Days) | ★ 8.3M | 1.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 431.45 | 4.67 |
| EPS | ★ 8.45 | 1.61 |
| Revenue | ★ $20,322,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $34.66 | $6.77 |
| Revenue Next Year | $23.38 | $5.89 |
| P/E Ratio | ★ $8.22 | $146.61 |
| Revenue Growth | ★ 48.63 | 41.60 |
| 52 Week Low | $56.12 | $154.50 |
| 52 Week High | $486.89 | $251.36 |
| Indicator | CVNA | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 64.18 |
| Support Level | $61.60 | $218.57 |
| Resistance Level | $73.18 | $247.52 |
| Average True Range (ATR) | 3.09 | 7.48 |
| MACD | 1.81 | 0.76 |
| Stochastic Oscillator | 84.50 | 68.64 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.